Figure 4From: A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activityIn vivoangiogenesis inhibition. (A) Subintestinal vessels (SIVs) under normal conditions are shown. (B) HB-002.1 at different doses (4.4, 14.7, 44Â ng) (left) was injected into the blood flow during embryogenic development of zebrafish. Endostatin at two doses (44, 100Â ng) was included in the study as positive controls (right). Representative Images from one of the ten zebra fishes in each group are shown. Arrows point to the number of SIVs in each group.Back to article page